Long-term Perimetric Stabilization with a Management Algorithm of Set Target Intraocular Pressure in Different Severities of Primary Angle-closure Glaucoma

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2021 Sep 28

PMID 34571622

Authors

Ramanjit Sihota

Jyoti Shakrawal

Ajay K Sharma

Amisha Gupta

Tanuj Dada

Veena Pandey

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate long-term perimetric stabilization at set Target (IOPs) in primary angle-closure glaucoma with visual field defects.

Methods: Two hundred forty-eight eyes, of 124 primary angle-closure glaucoma (PACG) patients on medical treatment, and 124 eyes, of 95 patients after trabeculectomy performed at least 5 years prior were evaluated. One hundred eighty-five eyes had a follow-up of ≥10 years. Target IOPs for mild, moderate, and severe glaucomatous optic neuropathy were set at ≤18, ≤15, and ≤12 mmHg, respectively. Progression was evaluated by event-based changes on guided progression analysis. Primary outcome measure was therapy required to achieve individualized Target IOP. Secondary outcome measure was assessment of perimetric change over time.

Results: Mean baseline IOP was 23.34 ± 6.16 mmHg in medically treated and 36.08 ± 9.73 mmHg in surgically treated eyes (P = 0.0001). All eyes with a baseline IOP of <25 mmHg were on medications alone, 65.33%, of those with a baseline IOP of 25-30 mmHg were on medications, while 34.67% required trabeculectomy. In total, 91.4% of eyes with a baseline IOP of >30 mmHg underwent a trabeculectomy for achieving Target IOP. Perimetric stabilization was achieved in 98.17% of PACG eyes. "Target" IOP was achieved for mild, moderate, and severe glaucomatous optic neuropathy, medically in 90.2, 73.9, and 29.7%, and surgery was required in 9.8, 26.1, and 70.3%, respectively. Overall analysis found that percentage reduction in IOP was significantly more after trabeculectomy than medical treatment, 64.16 ± 14.91 and 43.61 ± 13.73%, P = 0.0001. Decrease in IOP was significantly greater 5-9 years after trabeculectomy, in comparison to ≥10 years, P = 0.001.

Conclusion: Medications controlled IOP to "Target" in PACG eyes with mild and moderate glaucoma for over ≥10 years, when the baseline IOP off treatment was <30 mmHg. Trabeculectomy was necessary in PACG eyes having severe glaucomatous optic neuropathy, or with a baseline IOP of >30 mmHg to achieve Target IOP. These appropriate initial therapeutic interventions and Target IOPs are therefore suggested as a clinically validated algorithm of care for different severities of PACG.

References

Beckers H, Kinders K, Webers C . Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol. 2003; 241(2):106-10. DOI: 10.1007/s00417-002-0621-5. View

Damji K, Behki R, Wang L . Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol. 2003; 38(3):189-97. DOI: 10.1016/s0008-4182(03)80060-1. View

Kashiwagi K, Kogure S, Mabuchi F, Chiba T, Yamamoto T, Kuwayama Y . Change in visual acuity and associated risk factors after trabeculectomy with adjunctive mitomycin C. Acta Ophthalmol. 2016; 94(7):e561-e570. DOI: 10.1111/aos.13058. View

Kirwan J, Lockwood A, Shah P, Macleod A, Broadway D, King A . Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology. 2013; 120(12):2532-2539. DOI: 10.1016/j.ophtha.2013.07.049. View

. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000; 130(4):429-40. DOI: 10.1016/s0002-9394(00)00538-9. View

Sihota R . An Indian perspective on primary angle closure and glaucoma. Indian J Ophthalmol. 2010; 59 Suppl:S76-81. PMC: 3038512. DOI: 10.4103/0301-4738.73687. View

Cillino S, Casuccio A, Di Pace F, Cagini C, Ferraro L, Cillino G . Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up. BMC Ophthalmol. 2016; 16:24. PMC: 4779569. DOI: 10.1186/s12886-016-0198-0. View

Sihota R, Angmo D, Ramaswamy D, Dada T . Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018; 66(4):495-505. PMC: 5892050. DOI: 10.4103/ijo.IJO_1130_17. View

Landers J, Martin K, Sarkies N, Bourne R, Watson P . A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology. 2011; 119(4):694-702. DOI: 10.1016/j.ophtha.2011.09.043. View

10.

Musch D, Gillespie B, Lichter P, Niziol L, Janz N . Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2008; 116(2):200-7. PMC: 3316491. DOI: 10.1016/j.ophtha.2008.08.051. View

11.

Quigley H, Broman A . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-7. PMC: 1856963. DOI: 10.1136/bjo.2005.081224. View

12.

Salmon J . The role of trabeculectomy in the treatment of advanced chronic angle-closure glaucoma. J Glaucoma. 2009; 2(4):285-90. View

13.

Alsagoff Z, Aung T, Ang L, Chew P . Long-term clinical course of primary angle-closure glaucoma in an Asian population. Ophthalmology. 2000; 107(12):2300-4. DOI: 10.1016/s0161-6420(00)00385-7. View

14.

Tsai H, Liu C, Cheng C . Combined trabeculectomy and cataract extraction versus trabeculectomy alone in primary angle-closure glaucoma. Br J Ophthalmol. 2009; 93(7):943-8. DOI: 10.1136/bjo.2008.151803. View

15.

Li J, Lin X, Yu M . Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. Eur J Ophthalmol. 2014; 25(1):18-26. DOI: 10.5301/ejo.5000506. View

16.

Sihota R, Midha N, Selvan H, Sidhu T, Swamy D, Sharma A . Prognosis of different glaucomas seen at a tertiary center: A 10-year overview. Indian J Ophthalmol. 2017; 65(2):128-132. PMC: 5381291. DOI: 10.4103/ijo.IJO_875_16. View

17.

Romero P, Hirunpatravong P, Alizadeh R, Kim E, Nouri-Mahdavi K, Morales E . Trabeculectomy With Mitomycin-C: Outcomes and Risk Factors for Failure in Primary Angle-closure Glaucoma. J Glaucoma. 2017; 27(2):101-107. DOI: 10.1097/IJG.0000000000000842. View

18.

Law S, Modjtahedi S, Mansury A, Caprioli J . Intermediate-term comparison of trabeculectomy with intraoperative mitomycin-C between Asian American and Caucasian glaucoma patients: a case-controlled comparison. Eye (Lond). 2005; 21(1):71-8. DOI: 10.1038/sj.eye.6702128. View

19.

Maheshwari D, Kanduri S, Kadar M, Ramakrishnan R, Pillai M . Midterm outcome of mitomycin C augmented trabeculectomy in open angle glaucoma versus angle closure glaucoma. Indian J Ophthalmol. 2019; 67(7):1080-1084. PMC: 6611248. DOI: 10.4103/ijo.IJO_1328_18. View

20.

Sakai H, Shinjyo S, Nakamura Y, Nakamura Y, Ishikawa S, Sawaguchi S . Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients. J Ocul Pharmacol Ther. 2006; 21(6):483-9. DOI: 10.1089/jop.2005.21.483. View